Polyphor is a clinical stage biopharmaceutical company focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics against Gram-negative bacteria, the Outer Membrane Protein Targeting Antibiotics (OMPTA).

Products, services, technology

Balixafortide: Antagonist of CXCR4 in Phase III  in patients with advanced breast cancer

Inhaled Murepavadin:  Antibiotic against Pseudomonas aeruginosa in preclinical stage

POL6014 – Outlicensed to Santhera: Inhaled inhibitor of neutrophil elastase for treatment of severe lung diseases

Location
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    1996
  • Number of employees in Switzerland
    50-149
Key business